Personalized Genomics Market Latest Updated Report 2024-2031

Personalized Genomics Market to Record an Exponential CAGR of 16.96% by 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd.

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Personalized Genomics Market - (By Test Type (Oncology Testing, Infectious Disease Testing, Neurological Testing, Cardiovascular Testing, Others), By Technology (PCR-based Tests, Microarray-based Tests, Sequencing-based Tests, Others), By Application (Diagnostics, Precision Medicine, Wellness, Reproductive Health, Sports Nutrition & Health Lifestyle, Others), By End User (Hospitals & Clinics, Research Centers, Pharmaceutical & Biotechnology Companies, Diagnostic Laboratories, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
According to the latest research by InsightAce Analytic, the Global Personalized Genomics Market is valued at US$ 7.97 Billion in 2022, and it is expected to reach US$ 32.15 Billion by 2031, with a CAGR of 16.96% during the forecast period of 2023-2031.

Personalized genomics, or precision medicine, involves tailoring medical care and treatments to individual genetic characteristics. It relies on analyzing a person's genetic makeup to make more informed decisions about their health, disease susceptibility, and response to specific treatments. The growth of the worldwide market is primarily driven by the advancement of efficient and innovative technologies, growing public consciousness about personalized genomics, an upsurge in government activities worldwide, and the expansion of genetic database establishment. Moreover, the worldwide market for personalized medicine would have additional opportunities due to the growing use of customized genomics in emerging economies, neurology, pulmonary, antiviral, and psychiatric. The demand for quick-acting treatment methods, the growing number of patients with severe illnesses like cancer and diabetes, the growing use of combination drug therapies, the ageing population worldwide, and the rise in personalized genomics clinical trials in neurology departments are all factors propelling the growth of the personalized genomics market over the projected period.

Get Free Sample Copy of Report : https://www.insightaceanalytic.com/request-sample/2273

List of Prominent Players in the Personalized Genomics Market:
• 23andMe
• Mapmygenome
• Invitea
• Genetic Technology Limited
• Lonza
• Interleukin Genetics, Inc
• DNA Genotek
• Helix
• MyHeritage
• Pathway Genomics
• Veritas Genetics
• Xcode
• Color Genomics
• Myriad Genetics
• Quest Diagnostics
• Bio-Rad Laboratories, Inc.
• Illumina
• Thermo Fisher Scientific
• Qiagen
• Genomic Health
• Nebula Genomics
• Eastern Biotech and Life Sciences,
• uBiome, Inc
• Others

Market Dynamics:

Drivers-
Globally, there is an increasing focus on early disease diagnosis and preventative healthcare. The detection of genetic risk factors and predispositions to diseases such as cancer, cardiovascular diseases, neurological problems, etc., is made possible by genomic testing. Early diagnosis and best-practice treatment planning are made possible by this. Knowing one's genetic risks through personalized genomics enables people to take preventive action through lifestyle modifications and routine screenings. Genetic testing, for instance, can forecast a person's likelihood of developing diseases like colorectal or breast cancer. To reduce the risk of disease, high-risk persons can reduce their exposure to harmful substances, adopt more appropriate lifestyle choices, and use preventive medication. The adoption of genomics is being aided greatly by its potential for early diagnosis and illness prevention.

Challenges:
Despite efforts to streamline procedures by organizations like the U.S. FDA, the regulatory environment for the clearance of genetic tests is still unclear. Better frameworks tailored to the fast iterative process of genomics are required. Furthermore, a large number of novel genetic assays lack complete regulatory approval. For example, the FDA has certified relatively few companion diagnostics that direct focused therapy. Clinical integration is delayed by unclear laws, particularly about LDTs and DTC diagnostics. As genomics advances, regulations must effectively achieve a harmonious equilibrium between safety and innovation.

Regional Trends:
The North American Personalized Genomics Market is expected to record a major market revenue share, and it is projected to grow at a high CAGR in the near future. Numerous variables that support the expansion and advancement of personalized genomic services and goods have an impact on the personalized genomics market in North America. The area is a major centre for advances in genomics research, technology, and healthcare. The healthcare system in North America is highly advanced, with a strong emphasis on innovation and the adoption of cutting-edge technologies. This has facilitated the advancement and extensive implementation of customized medicine technology in the region.

Curious About This Latest Version Of The Report? Enquiry Before Buying: https://www.insightaceanalytic.com/enquiry-before-buying/2273

Recent Developments:

• In Jan 2023, QIAGEN and Helix formed an exclusive cooperation to enhance the development of next-generation sequencing companion diagnostics for genetic illnesses. QIAGEN had the sole responsibility for marketing and contracting Helix's companion diagnostic services in the United States. The collaboration utilized the Helix® Laboratory technology, which has received the initial U.S. Food & Drug Administration de novo class II authorization for a comprehensive exome sequencing technology.

• In Dec 2021, Lonza and Agilent announced a strategic collaboration with the potential to revolutionize the manufacturing and realization of individualized cell treatments. The firms sought to establish the optimal Critical Quality Attributes (CQAs) necessary for cell treatments and developed enhanced analysis packages to provide higher-quality therapeutic goods with more uniformity.

Segmentation of Personalized Genomics Market-
By Test Type-
• Oncology Testing
• Infectious Disease Testing
• Neurological Testing
• Cardiovascular Testing
• Others
By Technology-
• PCR-based Tests
• Microarray-based Tests
• Sequencing-based Tests
• Others
By Application-
• Diagnostics
• Precision Medicine
• Wellness
• Reproductive Health
• Sports Nutrition & Health
• Lifestyle
• Others
By End-User-
• Hospitals & Clinics
• Research Centers
• Pharmaceutical & Biotechnology Companies
• Diagnostic Laboratories
• Others
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

For More Customization @ https://www.insightaceanalytic.com/report/personalized-genomics-market/2273

Commercial Office Unit No.3050, 3rd Floor Marvel Fuego, Magarpatta Rd, Hadapsar,
Pune, Maharashtra 411028

Contact Us:
InsightAce Analytic Pvt. Ltd.
Tel.: +1 718 593 4405
Email: info@insightaceanalytic.com
Site Visit: www.insightaceanalytic.com
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions.
Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses.
We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products.
Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

This release was published on openPR.